MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617097670 A) filed by Pamoja Therapeutics B. V. on August 12, 2026, for Highly Concentrated Liquid Aqueous Pyronaridine Formulation.
Inventors include Platteeuw, Johannes Jan; and Michorius, Johannes Albertus.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The invention relates to a liquid aqueous formulation of pyronaridine for use in medical treatment, said liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol/ml of dissolved pyronaridine, having a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm/kg) to the pyronaridine concentration of the formulation (in mmol/mL) is less than 2.0. The invention also relates to a sterile liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol/ml of dissolved pyronaridine, having an osmolality in the range of 0.15 to 0.60 Osm/kg, a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm/kg) to the pyronaridine concentration of the formulation (in mmol/mL) is less than 2.0. The concentrated aqueous pyronaridine formulation of the present invention is perfectly suited for intramuscular administration, but can also suitably be administered subcutaneously, intranasally, orally, intraperitonially or intravenously.
Disclaimer: Curated by HT Syndication.
